Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a Buy rating and $17 price target, citing the company's "differentiated" at-home agitation franchise, expanding BXCL501 neuropsychiatry options, and what it calls "an extreme disconnect between enterprise value and risk-adjusted cash flow potential."
